Results 131 to 140 of about 512 (172)
An update of neurological manifestations of vasculitides and connective tissue diseases: a literature review. [PDF]
Einstein (Sao Paulo), 2015 Bougea A +4 more
europepmc +1 more source
Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. [PDF]
Rheumatology (Oxford), 2007 Curtis JR +8 more
europepmc +1 more source
Biological drugs for the treatment of psoriasis in a public health system. [PDF]
Rev Saude Publica, 2014 Lopes LC +5 more
europepmc +1 more source
Management of acute graft-versus-host disease in children. [PDF]
Pediatr Clin North Am, 2010 Carpenter PA, Macmillan ML.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Dermatologic Therapy, 2004
Infliximab is a chimeric monoclonal antibody that interferes with the actions of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Clinical trials of infliximab have demonstrated a rapid and substantial response in patents with psoriasis and psoriatic arthritis, substantiating the role of TNF-alpha in the immunopathogenesis of ...
Laura S, Winterfield, Alan, Menter
+5 more sources
Infliximab is a chimeric monoclonal antibody that interferes with the actions of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Clinical trials of infliximab have demonstrated a rapid and substantial response in patents with psoriasis and psoriatic arthritis, substantiating the role of TNF-alpha in the immunopathogenesis of ...
Laura S, Winterfield, Alan, Menter
+5 more sources
Expert Opinion on Pharmacotherapy, 2001
Infliximab (Remicade, Centocor, Inc.) is an intravenously administered monoclonal antibody to TNF proven effective in the treatment of moderate to severe Crohn's disease (CD). Its introduction in October 1998 was heralded by some as the most important addition to therapy for this condition in 50 years. Since then, additional indications have been added
E, Valle, M, Gross, S J, Bickston
openaire +3 more sources
Infliximab (Remicade, Centocor, Inc.) is an intravenously administered monoclonal antibody to TNF proven effective in the treatment of moderate to severe Crohn's disease (CD). Its introduction in October 1998 was heralded by some as the most important addition to therapy for this condition in 50 years. Since then, additional indications have been added
E, Valle, M, Gross, S J, Bickston
openaire +3 more sources
Interações Medicamentosas Entre Infliximabe e Medicamentos de Uso Domiciliar em Pacientes Com Artrite Reumatoide: Drug Interactions Between Infliximab And Home Use Medications in Patients With Rheumatoid Arthritis [PDF]
Revista Interdisciplinar De Estudos Em SaúdeA artrite reumatoide (AR) é uma doença crônica, autoimune e inflamatória, o infliximabe é utilizado para o seu tratamento. Pacientes com AR possuem diversas comorbidades associadas e muitas vezes fazem uso de polifarmácia, com risco aumentado para ...
Rochele Mosmann Menezes +2 more
exaly +2 more sources
Drugs, 2005
Infliximab is a monoclonal antibody that binds to tumour necrosis factor-alpha and blocks its biological activity. It is approved for use in patients with rheumatoid arthritis, Crohn's disease and ankylosing spondylitis.black triangle In well designed, placebo-controlled trials of 12 or 24 weeks' duration in patients with active ankylosing spondylitis,
Dean M, Robinson, Gillian M, Keating
openaire +2 more sources
Infliximab is a monoclonal antibody that binds to tumour necrosis factor-alpha and blocks its biological activity. It is approved for use in patients with rheumatoid arthritis, Crohn's disease and ankylosing spondylitis.black triangle In well designed, placebo-controlled trials of 12 or 24 weeks' duration in patients with active ankylosing spondylitis,
Dean M, Robinson, Gillian M, Keating
openaire +2 more sources